- InterCure (INCR.U) acquires one of Israel’s leading active medical cannabis trade houses & initiates a home delivery service in collaboration with UPS
- The trading house is approved by the Israeli Medical Cannabis Agency (IMCA) and is one of the leading operating trading houses in the country
- As part of GMP regulations, medical cannabis products can dispense through IMCA approved pharmacies which supply their inventories
- This expansion positions InterCure to meet the growing demand for medical cannabis products as the patient’s community continues to grow
- InterCure Ltd. (INCR.U) is trading at USD$6.75
InterCure Ltd. (INCR.U) has signed a definitive agreement to acquire a licensed active medical cannabis trading house and two pharmacies.
The trading house is approved by the Israeli Medical Cannabis Agency (IMCA) and is one of the leading operating trading houses in the country, authorized to distributing GMP medical cannabis products to pharmacies.
As part of GMP regulations, medical cannabis products can dispense through IMCA approved pharmacies which supply their inventories only from authorized medical cannabis trade houses.
As part of the acquisition, two pharmacies, located in central Israel added to Inter Cure’s leading medical-focused, pharmacy chain, expanding its footprint to 12 points of sale in key locations across Israel.
This expansion positions InterCure to meet the growing demand for medical cannabis products as the patient’s community continues to grow, currently averaging 4 per cent per month.
The acquisition is expected to be accretive beginning from Q3 2021 supporting InterCure’s vertically integrated model. The transaction is subject to regulatory approvals.
In addition, as demand for medical cannabis products during the military conflict in Israel remains solid – the Company initiated a medical cannabis home delivery program in collaboration with UPS.
For the first time, patients in Israel can order InterCure’s high-quality branded products directly to their home with same-day delivery using UPS’s world-renowned carrier service.
InterCure (dba Canndoc) is one of the leading and the most profitable Israeli cannabis company.
Canndoc, a wholly-owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
InterCure Ltd. (INCR.U) is trading at USD$6.75 .